Plasma Immunoreactive Atrial Natriuretic Peptide Levels After Subcutaneous α-hANP Injection in Normal Humans

Publisher Website
Google Scholar
Abstract
The plasma hormone and urine effects of .mu.g of .alpha.-human atrial natriuretic peptide (.alpha.-hANP) given by subcutaneous (s.c.) injection, were studied in eight healthy male volunteers. A control s.c. injection was administered on a separate day, and the study was single-blind. The peak immunoreactive atrial natriuretic peptide (IR-ANP) level of 29.4 .+-. 4.4 pmol/L reached at 5 min was threefold higher than on the control day. Area under the IR-ANP response curve was .apprx. 1/33 of that after the same dose of .alpha.-hANP given by intravenous (i.v.) injection. .alpha.-hANP s.c. injection was not associated with significant effects on plasma renin activity (PRA), plasma aldosterone, or urine electrolyte excretion. It was concluded that only a small percentage of intact .alpha.-hANP is absorbed into the circulation after s.c. injection. With the dose of peptide and the injection vehicle chosen, .alpha.-hANP had little or no biological effect.